日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

miRNA-dependent resistance mechanisms to anti-hormonal therapies in estrogen receptor-positive breast cancer patients

雌激素受体阳性乳腺癌患者中miRNA依赖性抗激素疗法耐药机制

期刊:Molecular Therapy Oncology
影响因子:5.3
doi:10.1016/j.omton.2025.200941
Al Hashami, Zainab Salam; van der Vegt, Bert; Mourits, Marian J E; Kluiver, Joost; van den Berg, Anke
肿瘤
肿瘤免疫
信号转导
乳腺癌
miRNA
免疫/内分泌
发表日期：2025
文献求助 收藏

When cancer reaches the heart: a case series on rare myocardial and endocardial metastases from squamous cell carcinoma

癌症侵袭心脏：鳞状细胞癌罕见心肌和心内膜转移病例系列研究

期刊:
影响因子:
doi:10.22551/2025.46.1201.10311
Basuoni, Ahmed; Burney, Ikram; Al-Hashami, Z; Ahmed, Marwa; Kamel, Amany Hany Mohamed; de Oliveira Manoel, Airton Leonardo; Al Bulushi, Yarab; Dawelbeit, Waleed
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Tracheal necrosis after sandwich immunotherapy and stereotactic body radiotherapy for lung cancer

肺癌患者接受三明治式免疫疗法和立体定向放射治疗后出现气管坏死

期刊:African Journal of Thoracic and Critical Care Medicine
影响因子:
doi:10.7196/AJTCCM.2024.v30i2.1620
Bennji, S M; Jayakrishnan, B; Al-Hashami, Z; Mula-Hussain, L; Telugu, R B
肺癌
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2024
文献求助 收藏

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy

PD-L1 ≥ 50% 的 IV 期非小细胞肺癌患者接受一线帕博利珠单抗治疗的真实世界疗效：二线全身治疗的接受情况

期刊:Current Oncology
影响因子:3.4
doi:10.3390/curroncol30060402
Rittberg, Rebekah; Leung, Bonnie; Shokoohi, Aria; Pender, Alexandra; Wong, Selina; Al-Hashami, Zamzam; Wang, Ying; Ho, Cheryl
肺癌
肿瘤
肿瘤免疫
PD-L1
细胞生物学
发表日期：2023
文献求助 收藏

Invasive fungal infections in children with leukemia in a tertiary hospital in Oman: An eight-year review

阿曼一家三级医院白血病患儿侵袭性真菌感染：一项为期八年的回顾性研究

期刊:Current Medical Mycology
影响因子:
doi:10.22034/CMM.2023.345108.1447
Al Hajri, Hind; Al-Salmi, Widad; Al Hinai, Karima; Al-Housni, Saif; Al-Harrasi, Ahmed; Al Hashami, Hilal; Al-Hatmi, Abdullah M S
白血病
炎症/感染
微生物学
发表日期：2023
文献求助 收藏

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing

晚期非小细胞肺癌（PD-L1 TPS ≥ 50%）患者帕博利珠单抗给药间隔的替代方案：每3周给药一次与每6周给药一次的比较

期刊:Current Oncology
影响因子:3.4
doi:10.3390/curroncol29110685
Jones, Lauren; Rittberg, Rebekah; Leung, Bonnie; Shokoohi, Aria; Pender, Alexandra; Wong, Selina; Al-Hashami, Zamzam; Wang, Ying; Ho, Cheryl
肺癌
肿瘤
肿瘤免疫
PD-L1
细胞生物学
发表日期：2022
文献求助 收藏

Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization

小细胞肺癌二线鲁比替定治疗的真实世界患者资格：了解流行病学并估算医疗保健利用率

期刊:Current Oncology
影响因子:3.4
doi:10.3390/curroncol29120765
Rittberg, Rebekah; Leung, Bonnie; Al-Hashami, Zamzam; Ho, Cheryl
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

2022 International Cancer Education Conference Late-Breaking Abstracts

2022年国际癌症教育大会最新摘要

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-023-10800-x
Leung, Bonnie; Shokoohi, Aria; Al-Hashami, Zamzam; Moore, Sara; Pender, Alexandra; Wong, Selina K; Wang, Ying; Wu, Jonn; Ho, Cheryl
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer

广泛期小细胞肺癌患者接受铂类双药联合免疫检查点抑制剂治疗的真实世界适应症

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2022.1002385
Rittberg, Rebekah; Leung, Bonnie; Al-Hashami, Zamzam; Ho, Cheryl
肺癌
肿瘤
肿瘤免疫
细胞生物学
免疫/内分泌
发表日期：2022
文献求助 收藏

Effect of targeted therapy and immunotherapy on advanced nonsmall-cell lung cancer outcomes in the real world

靶向治疗和免疫治疗对晚期非小细胞肺癌真实世界预后的影响

期刊:Cancer Medicine
影响因子:3.1
doi:10.1002/cam4.4427
Shokoohi, Aria; Al-Hashami, Zamzam; Moore, Sara; Pender, Alexandra; Wong, Selina K; Wang, Ying; Leung, Bonnie; Wu, Jonn; Ho, Cheryl
肺癌
肿瘤
肿瘤免疫
细胞生物学
免疫/内分泌
发表日期：2022
文献求助 收藏